The BITE study - Bleeding In Thrombocytopenia Explained: A nationwide epidemiological and laboratory case cohort study investigating risk factors for bleeding in hemato-oncology patients

The BITE study - Bleeding In Thrombocytopenia Explained: A nationwide epidemiological and laboratory case cohort study investigating risk factors for bleeding in hemato-oncology patients - The BITE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55653

Enrollment

1000

Registered

2018-04-04

Start date

2018-12-04

Completion date

Unknown

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemato-oncological diseases malignant diseases of the blood.

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Admission in the hospital AND - Age >= 18 years AND - Hemato-oncology patient, including MDS and AA, admitted for treatment (chemotherapy, SCT) who is (expected to become) thrombocytopenic with platelet counts of

Exclusion criteria

Exclusion criteria: - Myeloproliferative disorders

Design outcomes

Primary

Measure	Time frame
- The presence of clinical factors and results of routinely performed laboratory tests compared between bleeding versus non-bleeding patients. - Presence of markers for coagulation-, platelet- and endothelial or vascular dysfunction compared between bleeding versus non-bleeding patients.	—

Countries

Netherlands

Outcome results